Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPA-pulsed DC vaccine in metastatic solid malignancies
NCT02705703Phase 2Withdrawn
- Sponsor
- Kiromic BioPharma, Inc.
- Start
- Jul 2017
- Primary completion
- Oct 2018
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
A Phase 2 trial of KiroVax in metastatic solid tumor, sponsored by Kiromic BioPharma, Inc.. Planned start Jul 2017; status: withdrawn.
02
Drugs
KiroVax
03
Conditions
metastatic solid tumor
Beyond the preview
Go deeper on NCT02705703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705703.